Clinical Trial Update: Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update comparing RKI983 at 0.05% and 0.10% to Xalatan in patients with primary open-angle glaucoma or ocular hypertension; phases 1 and 2 compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• RKI983
• Xalatan (latanoprost)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glaucoma, Ocular Hypertension | Phase 1, Phase 2 | Status: COMPLETED